DE69033040D1 - Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF) - Google Patents

Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)

Info

Publication number: DE69033040D1
Authority: DE; Germany
Prior art keywords: tgf; production; biologically active; active protein; beta
Prior art date: 1989-12-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69033040T

Other languages

English (en)

Other versions

DE69033040T2 (de

Inventor

Nico Dr Cerletti

Gary Kent Dr Mcmaster

David Dr Cox

Albert Dr Schmitz

Bernd Dr Meyhack

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-06

Filing date

1990-11-27

Publication date

1999-05-12

1990-11-27 Application filed by Novartis AG filed Critical Novartis AG

1999-05-12 Application granted granted Critical

1999-05-12 Publication of DE69033040D1 publication Critical patent/DE69033040D1/de

1999-09-09 Publication of DE69033040T2 publication Critical patent/DE69033040T2/de

2010-11-28 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 3
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Crystallography & Structural Chemistry (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Transplantation (AREA)
Physics & Mathematics (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

DE69033040T 1989-12-06 1990-11-27 Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF) Expired - Lifetime DE69033040T2 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898927546A GB8927546D0 (en)	1989-12-06	1989-12-06	Process for the production of biologically active tgf-beta

Publications (2)

Publication Number	Publication Date
DE69033040D1 true DE69033040D1 (de)	1999-05-12
DE69033040T2 DE69033040T2 (de)	1999-09-09

Family

ID=10667491

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69033040T Expired - Lifetime DE69033040T2 (de)	1989-12-06	1990-11-27	Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)

Country Status (23)

Country	Link
US (2)	US5650494A (de)
EP (2)	EP0891985A1 (de)
JP (1)	JP3048061B2 (de)
KR (1)	KR100203230B1 (de)
AT (1)	ATE178616T1 (de)
AU (1)	AU638075B2 (de)
CA (1)	CA2031430C (de)
DE (1)	DE69033040T2 (de)
DK (1)	DK0433225T3 (de)
ES (1)	ES2132066T3 (de)
FI (1)	FI103278B1 (de)
GB (1)	GB8927546D0 (de)
GR (1)	GR3030703T3 (de)
HU (1)	HU218144B (de)
IE (2)	IE990992A1 (de)
IL (1)	IL96549A (de)
MX (1)	MX172600B (de)
NO (1)	NO301768B1 (de)
NZ (1)	NZ236333A (de)
PH (1)	PH31649A (de)
PT (1)	PT96068B (de)
SG (1)	SG52690A1 (de)
ZA (1)	ZA909762B (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6150328A (en)	1986-07-01	2000-11-21	Genetics Institute, Inc.	BMP products
GB8927546D0 (en) *	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
EP0547102B1 (de) *	1990-09-05	1998-07-08	Southern Cross Biotech Pty.Ltd.	In lösung bringen von proteinen in aktiver form
GB9106678D0 (en) *	1991-03-28	1991-05-15	Ferguson Mark W J	Wound healing
WO1993009229A1 (en) *	1991-11-04	1993-05-13	Genetics Institute, Inc.	Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US20080139474A1 (en) *	1991-11-04	2008-06-12	David Israel	Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
AU2738392A (en) *	1991-11-11	1993-05-13	Ciba-Geigy Ag	Novel hybrid transforming growth factors
US5288931A (en) *	1991-12-06	1994-02-22	Genentech, Inc.	Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
DE69327645T2 (de) *	1992-02-12	2000-09-07	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh	Dna-sequenzen kodierend für neuartige wachstums-/differentierungsfaktoren
GB9206861D0 (en) *	1992-03-28	1992-05-13	Univ Manchester	Wound healing and treatment of fibrotic disorders
US6884787B2 (en) *	2001-07-14	2005-04-26	Isis Pharmaceuticals, Inc.	Antisense modulation of transforming growth factor-beta 3 expression
DE4243729A1 (de) *	1992-12-23	1994-06-30	Behringwerke Ag	Verfahren zur Reaktivierung von gereinigten Membranproteinen
CA2151597A1 (en) *	1993-01-08	1994-07-21	Robert L. Garlick	Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
JP3555952B2 (ja)	1993-04-30	2004-08-18	バイオグノスティック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング	トランスフォーミング成長因子−β（ＴＧＦ‐β）の免疫抑制効果の治療用アンチセンス−オリゴヌクレオチド類
US5663304A (en) *	1993-08-20	1997-09-02	Genentech, Inc.	Refolding of misfolded insulin-like growth factor-I
US6291206B1 (en)	1993-09-17	2001-09-18	Genetics Institute, Inc.	BMP receptor proteins
US5411940A (en) *	1993-09-29	1995-05-02	Alcon Laboratories, Inc.	Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
JPH08503969A (ja) *	1993-09-29	1996-04-30	アルコンラボラトリーズ，インコーポレイテッド	増殖因子と組織形成抑制剤を含有する組成物
PT733109E (pt)	1993-12-07	2006-07-31	Genetics Inst Llc	Proteinas morfogeneticas dos 0ss0s pmo-12 e pmo-13 e as suas composicoes para inducao de tendao
US6027919A (en)	1993-12-07	2000-02-22	Genetics Institute, Inc.	BMP-12 and BMP-13 proteins and DNA encoding them
US5399677A (en) *	1993-12-07	1995-03-21	Genetics Institute, Inc.	Mutants of bone morphogenetic proteins
TW440566B (en) *	1994-07-25	2001-06-16	Novartis Ag	Novel process for the production of biologically active dimeric protein
CA2194177A1 (en) *	1994-07-25	1996-02-08	Jui Yoa Chang	Process for folding of proteins like recombinant hirudin or epidermal growth factor
TW517059B (en) *	1994-07-25	2003-01-11	Ciba Geigy Ag	New process for the production of biologically active protein
ATE325131T1 (de)	1995-04-19	2006-06-15	Bioph Biotech Entw Pharm Gmbh	Neues protein und verfahren zu dessen herstellung
US5714371A (en) *	1995-05-12	1998-02-03	Schering Corporation	Method for refolding insoluble aggregates of hepatitis C virus protease
US5800811A (en) *	1995-06-06	1998-09-01	Hall; Frederick L.	Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US6352972B1 (en) *	1995-06-06	2002-03-05	Marcel E. Nimni	Bone morphogenetic proteins and their use in bone growth
US6040431A (en)	1995-06-07	2000-03-21	Stryker Corporation	Single chain analogs of the TGF-β superfamily (morphons)
WO1997016556A1 (en)	1995-10-30	1997-05-09	Massachusetts Institute Of Technology	Rationally designed polysaccharide lyases derived from heparinase i
DE69636739T2 (de) *	1995-12-21	2007-10-18	Ajinomoto Co., Inc.	Verfahren zur rückfaltung von menschlichem activin a
WO1997026277A2 (en) *	1996-01-22	1997-07-24	Creative Biomolecules, Inc.	Morphogen analogs and methods for producing them
US20030185792A1 (en) *	1996-01-22	2003-10-02	Curis, Inc.	Morphogen analogs of bone morphogenic proteins
US6664227B1 (en)	1996-03-01	2003-12-16	Genetics Institute, Llc	Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7811793B2 (en)	1996-12-25	2010-10-12	Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh	Process for preparing purified active monomer of bone-derived factor
US6500920B1 (en) *	1997-06-19	2002-12-31	St. Louis University	Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
US7723473B2 (en)	1997-06-19	2010-05-25	St. Louis University	Peptide antagonists of TGF-beta family members and therapeutic uses thereof
DE69714035T2 (de)	1997-08-14	2003-03-06	Sulzer Innotec Ag, Winterthur	Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US20020052026A1 (en)	1997-10-08	2002-05-02	Steven M. Vicik	Methods of refolding proteins
DE19749259A1 (de) *	1997-11-07	1999-05-12	Dade Behring Marburg Gmbh	Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
JP4768121B2 (ja) *	1998-02-05	2011-09-07	グラクソスミスクラインバイオロジカルズソシエテアノニム	Ｍａｇｅファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用
US6057128A (en)	1998-03-17	2000-05-02	Genetics Institute, Inc.	MU-1, member of the cytokine receptor family
FR2776521B1 (fr) *	1998-03-27	2000-12-15	Pf Medicament	Utilisation de conjugues p40 actifs par voie nasale
US7056504B1 (en)	1998-08-27	2006-06-06	Massachusetts Institute Of Technology	Rationally designed heparinases derived from heparinase I and II
EP1109919A2 (de)	1998-08-27	2001-06-27	Massachusetts Institute Of Technology	Von heparinase i und ii abgeleitete heparinasen
US6933272B1 (en)	1998-09-22	2005-08-23	Erik Helmerhorst	Use of non-peptidyl compounds for the treatment of insulin related ailments
CA2657302A1 (en)	1998-10-07	2000-04-13	Hermann Oppermann	Modified tgf-.beta. superfamily proteins
US6846906B1 (en)	1998-10-07	2005-01-25	Stryker Corporation	Modified proteins of the TGF-β superfamily, including morphogenic proteins
US6677432B1 (en)	1998-10-07	2004-01-13	Stryker Corporation	Mutations of the C-terminal portion of TGF-β superfamily proteins
US7087577B2 (en)	1998-10-16	2006-08-08	Zimmer Orthobiologies, Inc.	Method of promoting natural bypass
US6992066B2 (en)	1998-10-16	2006-01-31	Zimmer Orthobiologics, Inc.	Povidone-containing carriers for polypeptide growth factors
ES2146552B1 (es) *	1998-11-24	2001-04-16	Inst Cientifico Tecnol Navarra	Peptidos inhibidores de tgf/31
EP1142908A4 (de) *	1999-01-07	2002-05-22	Takeda Chemical Industries Ltd	Methode zum herstellen von aktivierten proteinen
US6727224B1 (en)	1999-02-01	2004-04-27	Genetics Institute, Llc.	Methods and compositions for healing and repair of articular cartilage
DE19906096A1 (de)	1999-02-13	2000-08-17	Walter Sebald	Protein mit einem Heparin-bindenden Epitop
US7412332B1 (en)	1999-04-23	2008-08-12	Massachusetts Institute Of Technology	Method for analyzing polysaccharides
DE19944626A1 (de) *	1999-09-17	2001-03-22	Knoell Hans Forschung Ev	Verfahren zur Herstellung von dimeren, biologisch aktiven knochenmorphogenetischen Proteinen
AU774427B2 (en)	1999-10-15	2004-06-24	Fidia Advanced Biopolymers S.R.L.	Formulations of hyaluronic acid for delivery of osteogenic proteins
ES2527853T3 (es)	2000-03-08	2015-01-30	Massachusetts Institute Of Technology	Heparinasa III y sus usos
DE10026713A1 (de) *	2000-05-30	2001-12-06	Walter Sebald	Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
US7081240B1 (en) *	2000-06-28	2006-07-25	Zimmer Orthobiologics, Inc.	Protein mixtures for wound healing
PT1319183E (pt)	2000-09-12	2009-06-29	Massachusetts Inst Technology	Métodos e produtos relacionados a heparina de baixo peso molecular
WO2002032406A2 (en)	2000-10-18	2002-04-25	Massachusetts Institute Of Technology	Methods and products related to pulmonary delivery of polysaccharides
US7442370B2 (en)	2001-02-01	2008-10-28	Biogen Idec Ma Inc.	Polymer conjugates of mutated neublastin
ATE517909T1 (de) *	2001-02-23	2011-08-15	Immunex Corp	Effizientes gewinnungsverfahren von korrekterweise rückgefalteten proteinen
US7276580B2 (en)	2001-03-12	2007-10-02	Biogen Idec Ma Inc.	Neurotrophic factors
CA2449008A1 (en)	2001-06-01	2002-12-12	Wyeth	Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en)	2001-06-08	2006-12-01	Wyeth Corp	Calcium phosphate delivery vehicles for osteoinductive proteins
FI117667B (fi)	2001-07-05	2007-01-15	Univ Zuerich	Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
WO2003028630A2 (en)	2001-10-04	2003-04-10	Genetics Institute Llc.	Methods and compositions for modulating interleukin-21 receptor activity
US7232802B2 (en)	2001-12-21	2007-06-19	Zimmer Orthobiologics, Inc.	Compositions and methods for promoting myocardial and peripheral angiogenesis
RU2295535C2 (ru) *	2002-02-05	2007-03-20	Джимонат С.П.А.	Рекомбинантный плацентарный фактор роста и способ его получения
ES2284816T3 (es) *	2002-02-05	2007-11-16	Geymonat S.P.A.	Proceso de produccion de un factor de crecimiento placentario recombinante.
US7622562B2 (en)	2002-06-26	2009-11-24	Zimmer Orthobiologics, Inc.	Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
JP2006508049A (ja) *	2002-08-13	2006-03-09	ワイエス	増殖因子βタンパク質を形質転換するための可溶化賦形剤としてのペプチド
JP4571776B2 (ja) *	2002-11-05	2010-10-27	Ｊｘ日鉱日石エネルギー株式会社	潤滑油組成物
US7074412B2 (en)	2003-01-30	2006-07-11	The University Of Zurich	Pharmaceutical composition
CA2522364C (en)	2003-04-18	2014-12-09	Biogen Idec Ma Inc.	Polymer-conjugated glycosylated neublastin
CA2537735C (en)	2003-09-12	2018-07-24	Wyeth	Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
EP2338442B1 (de)	2003-12-11	2013-01-30	Isto Technologies Inc.	Teilchenförmiges Knorpelsystem
WO2006023781A2 (en) *	2004-08-19	2006-03-02	Biogen Idec Ma Inc.	Neublastin variants
EP1784203B1 (de) *	2004-08-19	2010-06-30	Biogen Idec MA Inc.	Rückfaltung von proteinen der transforming-growth-factor-beta-familie
WO2006081379A1 (en) *	2005-01-26	2006-08-03	Wyeth	Use of sfrps as markers of bmp activity
KR20070107703A (ko)	2005-02-14	2007-11-07	와이어쓰	인터루킨-１７ｆ 항체 및 기타 ｉｌ-１７ｆ 신호전달안타고니스트 및 그의 용도
CA2596986A1 (en)	2005-02-14	2006-08-24	Wyeth	Use of il-17f in diagnosis and therapy of airway inflammation
EP1863518A2 (de) *	2005-03-30	2007-12-12	Wyeth	VERFAHREN ZUR STIMULATION DES WAARWACHSTUMS MITTELS VERABREICHUNG VON BMPs
GT200600148A (es)	2005-04-14	2006-11-22		Metodos para el tratamiento y la prevencion de fibrosis
GB0514262D0 (en) *	2005-07-12	2005-08-17	Renovo Ltd	Promotion of epithelial regeneration
KR20080041640A (ko) *	2005-07-25	2008-05-13	트루비온 파마슈티칼스, 인코포레이티드	단백질 분산을 위한 조성물과 방법
GB0516204D0 (en) *	2005-08-06	2005-09-14	Riotech Pharmaceuticals Ltd	Methods
EP1916964A4 (de)	2005-08-26	2015-11-04	Zimmer Inc	Implantate und verfahren zur behebung, ersetzung und behandlung von gelenkkrankheiten
TWI501774B (zh)	2006-02-27	2015-10-01	Biogen Idec Inc	神經性病症之治療
US20100056440A1 (en) *	2006-03-01	2010-03-04	Biogen Idec Ma Inc.	Compositions and methods for administering gdnf ligand family proteins
US7582609B2 (en) *	2006-03-01	2009-09-01	Digna Biotech, S.L.	Method for the treatment of skin fibrosis and suitable compositions for such treatment
GB0604938D0 (en) *	2006-03-11	2006-04-19	Renovo Ltd	Proteins, nucleic acids and medicaments
GB0604966D0 (en) *	2006-03-11	2006-04-19	Renovo Ltd	Medicaments and proteins
GB0604964D0 (en) *	2006-03-11	2006-04-19	Renovo Ltd	Protein folding
ZA200900229B (en) *	2006-07-14	2010-04-28	Genentech Inc	Refolding of recombinant proteins
GB0617816D0 (en) *	2006-09-11	2006-10-18	Renovo Ltd	Nucleic acids and methods of protein expression
PL2078071T3 (pl)	2006-11-08	2015-07-31	Wyeth Llc	Racjonalnie opracowane pożywki do hodowli komórek
US8163549B2 (en)	2006-12-20	2012-04-24	Zimmer Orthobiologics, Inc.	Method of obtaining viable small tissue particles and use for tissue repair
WO2008128075A1 (en)	2007-04-12	2008-10-23	Isto Technologies, Inc.	Compositions and methods for tissue repair
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
NZ580947A (en)	2007-05-01	2012-05-25	Biogen Idec Inc	Compositions and methods for increasing vascularization
US20110135648A1 (en) *	2007-08-08	2011-06-09	Biogen Idec Ma Inc.	Anti-neublastin antibodies and uses thereof
EP2188371B1 (de)	2007-08-09	2017-12-20	Wyeth LLC	Verwendung von perfusion zur erhöhung der produktion von fed-batch-zellkulturen in bioreaktoren
CA2699454C (en)	2007-08-27	2012-07-24	Auxagen, Inc.	Methods for inhibiting tgf-.beta.
EP2341913B1 (de)	2008-09-16	2014-11-19	Saint Louis University	Verfahren zur verstärkung der tgf-beta-signalisierung
US8494140B2 (en) *	2008-10-30	2013-07-23	Centurylink Intellectual Property Llc	System and method for voice activated provisioning of telecommunication services
CA2739568C (en)	2008-10-31	2015-12-01	Shujun Sun	Purification of acidic proteins using ceramic hydroxyapatite chromatography
WO2011005488A1 (en)	2009-06-22	2011-01-13	Amgen Inc.	Refolding proteins using a chemically controlled redox state
CA2765154A1 (en)	2009-06-25	2010-12-29	Amgen Inc.	Capture purification processes for proteins expressed in a non-mammalian system
KR100991203B1 (ko) *	2010-05-10	2010-11-01	심영복	골형성 단백질의 정제 방법
JPWO2012029148A1 (ja)	2010-09-01	2013-10-28	株式会社オステオファーマ	組換えヒト骨形成タンパク質−２凍結乾燥製剤
HK1204568A1 (en) *	2012-02-10	2015-11-27	Japanic Corporation	Cosmetic product or skin regeneration promoter comprising nonhuman stem cell culture supernatant as starting material, and method for ion introduction for protein
US10188732B2 (en)	2012-08-06	2019-01-29	Biogen Ma Inc.	Methods and compositions for inactivating enveloped viruses
US20140178343A1 (en)	2012-12-21	2014-06-26	Jian Q. Yao	Supports and methods for promoting integration of cartilage tissue explants
US9758786B2 (en)	2016-02-09	2017-09-12	Autotelic, Llc	Compositions and methods for treating pancreatic cancer
US10919948B2 (en)	2016-12-30	2021-02-16	Biogend Therapeutics Co., Ltd.	Recombinant polypeptides, compositions, and methods thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA811970B (en) *	1980-03-27	1982-11-24	Lilly Co Eli	Process for producing an insulin
US4620948A (en) *	1982-12-22	1986-11-04	Genentech, Inc.	Purification and activity assurance of precipitated heterologous proteins
GR79124B (de) *	1982-12-22	1984-10-02	Genentech Inc
AU3108984A (en) *	1983-06-03	1985-01-04	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Purified transforming growth factor-beta derived from human platelets and placentas
ATE85080T1 (de) *	1984-02-17	1993-02-15	Genentech Inc	Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4572798A (en) *	1984-12-06	1986-02-25	Cetus Corporation	Method for promoting disulfide bond formation in recombinant proteins
US4731440A (en) *	1985-02-22	1988-03-15	Monsanto Company	Method of somatotropin solubilization using dimethylsulfone and naturation
IL78197A (en) *	1985-03-22	1991-07-18	Genentech Inc	Nucleic acid encoding tgf-beta and its uses
GB8508340D0 (en) *	1985-03-29	1985-05-09	Creighton T E	Production of protein
EP0208539A3 (de) *	1985-07-11	1988-08-03	Repligen Corporation	In Falten gelegte Proteine, durch Disulfid gebunden
US5453363A (en) *	1985-10-23	1995-09-26	Boehringer Mannheim Gmbh	Process for the activation of t-PA or Ing after genetic expression in prokaryotes
NZ222168A (en) *	1986-10-20	1991-05-28	Oncogene Science Inc	Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
JPH01501361A (ja) *	1986-11-17	1989-05-18	サンド・アクチエンゲゼルシャフト	新しいｔ細胞サプレッサー因子の生産およびその用途
FI100106B (fi) *	1986-12-05	1997-09-30	Novartis Ag	Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
US4931548A (en) *	1987-01-30	1990-06-05	Techne Corporation	Heterodimer form of transforming growth factor-beta
US5013653A (en) *	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
IL86090A (en) *	1987-04-16	1993-03-15	Cetus Oncology Corp	Production of purified, biologically active, bacterially produced recombinant human csf-1
DE3855986T2 (de) *	1987-05-11	1998-02-05	Chiron Corp	Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen
US5162507A (en) *	1987-05-11	1992-11-10	Cetus Corporation	Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
EP0293785A3 (de) *	1987-05-29	1990-05-02	Oncogen Limited Partnership	Klonierung und Expression von transformierendem Affenwachstumsfaktor-SS 1
US4985544A (en) *	1987-08-04	1991-01-15	Kyowa Hakko Kogyo Co., Ltd.	Process for renaturing fish growth hormone
US5061786A (en) *	1989-05-25	1991-10-29	Genentech, Inc.	Biologically active polypeptides based on transforming growth factor-β
GB8927546D0 (en) *	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
US5144006A (en) *	1991-06-13	1992-09-01	The Rockefeller University	Oxidative folding of peptide and protein substrates using hydrocarbon sulfoxides
AU2738392A (en) *	1991-11-11	1993-05-13	Ciba-Geigy Ag	Novel hybrid transforming growth factors

1989
- 1989-12-06 GB GB898927546A patent/GB8927546D0/en active Pending
1990
- 1990-11-27 EP EP98113487A patent/EP0891985A1/de not_active Withdrawn
- 1990-11-27 AT AT90810922T patent/ATE178616T1/de not_active IP Right Cessation
- 1990-11-27 DE DE69033040T patent/DE69033040T2/de not_active Expired - Lifetime
- 1990-11-27 SG SG1996007909A patent/SG52690A1/en unknown
- 1990-11-27 ES ES90810922T patent/ES2132066T3/es not_active Expired - Lifetime
- 1990-11-27 AU AU67018/90A patent/AU638075B2/en not_active Expired
- 1990-11-27 EP EP90810922A patent/EP0433225B1/de not_active Expired - Lifetime
- 1990-11-27 DK DK90810922T patent/DK0433225T3/da active
- 1990-11-30 JP JP2330871A patent/JP3048061B2/ja not_active Expired - Lifetime
- 1990-12-03 FI FI905956A patent/FI103278B1/fi active IP Right Grant
- 1990-12-04 CA CA002031430A patent/CA2031430C/en not_active Expired - Lifetime
- 1990-12-04 MX MX023579A patent/MX172600B/es unknown
- 1990-12-04 PT PT96068A patent/PT96068B/pt not_active IP Right Cessation
- 1990-12-04 NZ NZ236333A patent/NZ236333A/en unknown
- 1990-12-05 IL IL9654990A patent/IL96549A/xx not_active IP Right Cessation
- 1990-12-05 KR KR1019900019881A patent/KR100203230B1/ko not_active Expired - Lifetime
- 1990-12-05 NO NO905264A patent/NO301768B1/no not_active IP Right Cessation
- 1990-12-05 IE IE19990992A patent/IE990992A1/en not_active IP Right Cessation
- 1990-12-05 HU HU084/90A patent/HU218144B/hu unknown
- 1990-12-05 IE IE438690A patent/IE904386A1/en not_active IP Right Cessation
- 1990-12-05 ZA ZA909762A patent/ZA909762B/xx unknown
1994
- 1994-03-25 PH PH8001A patent/PH31649A/en unknown
1995
- 1995-06-07 US US08/486,057 patent/US5650494A/en not_active Expired - Lifetime
1997
- 1997-01-24 US US08/789,588 patent/US5922846A/en not_active Expired - Fee Related
1999
- 1999-07-07 GR GR990401786T patent/GR3030703T3/el unknown

Also Published As

Publication number	Publication date
HU908084D0 (en)	1991-06-28
FI905956A0 (fi)	1990-12-03
GR3030703T3 (en)	1999-11-30
EP0433225B1 (de)	1999-04-07
FI905956L (fi)	1991-06-07
PT96068B (pt)	1998-02-27
KR910012240A (ko)	1991-08-07
NO905264D0 (no)	1990-12-05
SG52690A1 (en)	1998-09-28
DE69033040T2 (de)	1999-09-09
ATE178616T1 (de)	1999-04-15
AU638075B2 (en)	1993-06-17
KR100203230B1 (ko)	1999-06-15
NO905264L (no)	1991-06-07
MX172600B (es)	1994-01-03
IE904386A1 (en)	1991-06-19
HUT56880A (en)	1991-10-28
IE990992A1 (en)	2000-12-13
CA2031430A1 (en)	1991-06-07
JP3048061B2 (ja)	2000-06-05
ES2132066T3 (es)	1999-08-16
CA2031430C (en)	2003-05-27
NO301768B1 (no)	1997-12-08
NZ236333A (en)	1992-03-26
EP0891985A1 (de)	1999-01-20
FI103278B (fi)	1999-05-31
AU6701890A (en)	1991-06-13
JPH03191791A (ja)	1991-08-21
HU218144B (hu)	2000-06-28
GB8927546D0 (en)	1990-02-07
EP0433225A1 (de)	1991-06-19
US5922846A (en)	1999-07-13
PT96068A (pt)	1991-09-30
IL96549A (en)	2000-10-31
PH31649A (en)	1999-01-12
DK0433225T3 (da)	1999-10-25
US5650494A (en)	1997-07-22
FI103278B1 (fi)	1999-05-31
IL96549A0 (en)	1991-09-16
ZA909762B (en)	1991-08-28

Publication	Publication Date	Title
DE69033040D1 (de)	1999-05-12	Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
DE3855921D1 (de)	1997-07-03	Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein
DE68923819D1 (de)	1995-09-21	Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
ATE114169T1 (de)	1994-12-15	Morphogenetisches knochenprotein.
DK140996A (da)	1996-12-09	Fremgangsmåde til fremstilling af 2,3,4,5-tetraflour-6-alkyl-benzoesyreforbindelser
ATE79763T1 (de)	1992-09-15	Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
HU9200548D0 (en)	1992-04-28	Improved activity process of recombined proteins
DE69427955D1 (de)	2001-09-20	Verfahren zur Herstellung von 2,2-Difluorketensilylacetalen und alpha,alpha-Difluor-beta -Silyloxy-1,3-Dioxolan-4-Propansäureestern
DE69331479D1 (de)	2002-03-14	Polyethylenglycol-Hirudin-Konjugate, deren Verfahren zur Herstellung und Verwendung für die Heilung von Thrombosen
DE3887068D1 (de)	1994-02-24	2,2-Dimethylchromenderivate, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
DE69018755D1 (de)	1995-05-24	Verfahren zur Herstellung von 3-(L-Pyroglutamyl)-L-thiazolidin-4-carbonsäure-Derivaten.
DE68919282D1 (de)	1994-12-15	Verfahren zur Herstellung von Cephalosporin und Zwischenverbindungen.
FR2635527B1 (fr)	1992-06-12	Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
ATE45675T1 (de)	1989-09-15	Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
ATE92056T1 (de)	1993-08-15	Verfahren zur herstellung von 5-chlor-3chlorsulfonyl-2-thiophencarbonsaeureestern.
ATE85893T1 (de)	1993-03-15	Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
ATE53384T1 (de)	1990-06-15	3-mercapto-2-oxo-1-pyrrolidinessigsaeurederivate verfahren zur herstellung und pharmazeutische zusammensetzungen die sie enthalten.

Legal Events

Date	Code	Title	Description
2000-05-04	8364	No opposition during term of opposition
2010-05-20	8328	Change in the person/name/address of the agent	Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336